Publications by authors named "E Gamelin"

Claim this Profile
P
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, Asim Amin, Christopher D Lao, Erick Gamelin

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma.
James Brugarolas, Gregory Obara, Kathryn E Beckermann, Brian Rini, Elaine T Lam, Erick Gamelin

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Ezra E W Cohen, Lisle Nabell, Deborah J Wong, Terry Day, Gregory A Daniels, Erick Gamelin

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Edward B Garon, Alexander I Spira, Melissa Johnson, Lyudmila Bazhenova, Joseph Leach, Erick Gamelin

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Marcus Noel, Eileen M O'Reilly, Brian M Wolpin, David P Ryan, Andrea J Bullock, Eric C Gamelin

Invest New Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis